1. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6(8):2209–19.
2. AstraZeneca. KOSELUGO (selumetinib) capsules, for oral use: US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf. Accessed 15 Apr 2020.
3. Yap YS, McPherson JR, Ong CK, et al. The NF1 gene revisited - from bench to bedside. Oncotarget. 2014;5(15):5873–92.
4. US Food & Drug Administration. FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas [media release]. 15 Apr 2020. https://www.fda.gov/.
5. European Medicines Agency. Public summary of opinion on orphan designation: selumetinib for the treatment of neurofibromatosis type 1. 2019. https://www.ema.europa.eu/. Accessed 15 Apr 2020.